Back

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors?

European Heart Journal - Cardiovascular Pharmacotherapy

29 October 2024
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY Chronic Heart Failure Risk Factors and Prevention

Contributors

Maki Komiyama
Maki Komiyama

Author

Koji Hasegawa
Koji Hasegawa

Author

National Hospital Organization Kyoto Medical Centre Kyoto , Japan

Giuseppe M C Rosano
Giuseppe M C Rosano

Author

You may be interested in
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Session
The strength of scientific integration